Risk of Stroke and Bleeding in Atrial Fibrillation Treated with Apixaban Compared with Warfarin

BACKGROUND: A previous FDA study reported a favorable benefit risk for apixaban compared with warfarin for stroke prevention in older non-valvular atrial fibrillation (NVAF) patients (≥ 65 years). However, it remains unclear whether this favorable benefit risk persists in other populations including...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Gen Intern Med
Prif Awduron: Bradley, Marie, Welch, Emily C., Eworuke, Efe, Graham, David J., Zhang, Rongmei, Huang, Ting-Ying
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer International Publishing 2020
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7728961/
https://ncbi.nlm.nih.gov/pubmed/32989717
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11606-020-06180-8
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg